Journal of the Korean Society of Laryngology, Phoniatrics and Logopedics (대한후두음성언어의학회지)

The Korean Society of Laryngology, Phoniatrics and Logopedics. (대한후두음성언어의학회)
권호 표지

Clinical Application of Botulinum Toxin to Functional Dysphonia

기능성 음성장애에서 보툴리늄 독소의 임상적 적용

  • Kim, Han Su (Department of Otorhinolaryngology-Head & Neck Surgery, School of Medicine, Ewha Womans University)
  • 김한수 (이화여자대학교 의과대학 이비인후과학교실)
  • Received : 2018.10.24
  • Accepted : 2019.05.03
  • Published : 2019.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Functional dysphonia (FD) is a disease entity which includes various voice disorders in the absence of structural or neurologic laryngeal pathology. Muscle tension dysphonia (MTD), psychogenic dysphonia are representative FD with completely different pathogenesis. Therefore there is no standard treatment modality for FD, the first step of treatment of FD is differentiating patient's voice symptoms from other organic voice disorders and other functional voice problems. MTD is a functional voice disorder caused by hyperfunction of intrinsic and extrinsic laryngeal musculature. Symptoms include increased vocal effort, roughness, fatigue and odynophonia. First line for MTD is indirect or direct voice therapy. Unfortunately, many patients with MTD improve with voice therapy alone. For these patients, various modalities tried; lidocaine application, surgical excision of the false vocal folds, and botulinum toxin injection, etc. Botulinum toxin injections are widely used in the field of otolaryngology, especially for spasmodic dysphonia. However, its use in FD or MTD has only been described in few case reports. The aim of this lecture is to evaluate the feasibility of botulinum toxin injection for FD, especially MTD.

Keywords

References

  1. Roy N. Functional dysphonia. Curr Opin Otolaryngol Head Neck Surg 2003;11(3):144-8. https://doi.org/10.1097/00020840-200306000-00002
  2. Kim HS. Controversies in Management of Functional Dysphonia. J Korean Soc Laryngol Phoniatr Logop 2014;25(2):86-9.
  3. Van Houtte E, Van Lierde K, D'Haeseleer E, Claeys S. The prevalence of laryngeal pathology in a treatment-seeking population with dysphonia. Laryngoscope 2010;120(2):306-12. https://doi.org/10.1002/lary.20696
  4. Kim HT. Functional dysphonia. In: Korean society of laryngology, phoniatrics and logopedic. editor The Laryngology, phoniatrics and logopedics. 2nd ed. Seoul: Beommun education; 2016. p.189-94.
  5. Belafsky PC, Postma GN, Reulbach TR, Holland BW, Koufman JA. Muscle tension dysphonia as a sign of underlying glottal insufficiency. Otolaryngol Head Neck Surg 2002;127(5):448-51. https://doi.org/10.1067/mhn.2002.128894
  6. Van Houtte E, Van Lierde K, Claeys S. Pathophysiology and treatment of muscle tension dysphonia: a review of the current knowledge. J Voice 2011;25(2):202-7. https://doi.org/10.1016/j.jvoice.2009.10.009
  7. Dworkin JP, Meleca RJ, Simpson ML, Garfield I. Use of topical lidocaine in the treatment of muscle tension dysphonia. J Voice 2000;14(4):567-74. https://doi.org/10.1016/S0892-1997(00)80012-0
  8. Roy N, Smith ME, Allen B, Merrill RM. Adductor spasmodic dysphonia versus muscle tension dysphonia: examining the diagnostic value of recurrent laryngeal nerve lidocaine block. Ann Otol Rhinol Laryngol 2007;116(3):161-8. https://doi.org/10.1177/000348940711600301
  9. Young N, Blitzer A. Management of supraglottic squeeze in adductor spasmodic dysphonia: a new technique. Laryngoscope 2007;117(11):2082-4. https://doi.org/10.1097/MLG.0b013e318124a97b
  10. Kendall KA, Leonard RJ. Treatment of ventricular dysphonia with botulinum toxin. Laryngoscope 1997;107(7):948-53. https://doi.org/10.1097/00005537-199707000-00022
  11. Rosen CA, Murry T. Botox for hyperadduction of the false vocal folds: a case report. J Voice 1999;13(2):234-9. https://doi.org/10.1016/S0892-1997(99)80026-5
  12. Pacheco PC, Karatayli-Ozgursoy S, Best S, Hillel A, Akst L. False vocal cord botulinum toxin injection for refractory muscle tension dysphonia: Our experience with seven patients. Clin Otolaryngol 2015;40(1):60-4. https://doi.org/10.1111/coa.12333
  13. Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol 1994;35(6):717-23. https://doi.org/10.1002/ana.410350613
  14. Sulica L, Louis ED. Clinical characteristics of essential voice tremor: a study of 34 cases. Laryngoscope 2010;120(3):516-28. https://doi.org/10.1002/lary.20702
  15. Justicz N, Hapner ER, Josephs JS, Boone BC, Jinnah HA, Johns MM 3rd. Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor. Laryngoscope 2016;126(1):113-7. https://doi.org/10.1002/lary.25485
  16. Kaye R, Blitzer A. Chemodenervation of the Larynx. Toxins (Basel) 2017;9(11):356. https://doi.org/10.3390/toxins9110356
  17. Gurey LE, Sinclair CF, Blitzer A. A new paradigm for the management of essential vocal tremor with botulinum toxin. Laryngoscope 2013;123(10):2497-501. https://doi.org/10.1002/lary.24073
  18. Benninger MS, Smith LJ. Noncosmetic uses of botulinum toxin in otolaryngology. Cleve Clin J Med 2015;82(11):729-32. https://doi.org/10.3949/ccjm.82a.14096